<DOC>
	<DOC>NCT00092976</DOC>
	<brief_summary>The primary objective of this clinical research study is to evaluate the safety and efficacy of ReFacto in subjects with hemophilia A undergoing major surgery monitored using the chromogenic substrate assay at the local laboratory.</brief_summary>
	<brief_title>Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Age ≥ 6 years Male previously treated patients (≥150 Exposure Days) with moderate or severe hemophilia A (i.e. ≤ 5% FVIII:C) who will undergo elective major surgery that is anticipated to require at least 6 consecutive days of daily factor VIII (FVIII) infusions (surgical and postsurgical prophylaxis) Ability to adhere to the protocol requirements Hypersensitivity to ReFacto, murine allergen, or hamster allergen 2 History of FVIII inhibitor or current inhibitor, defined as &gt; 0.6 BU Prior participation in this study Any concomitant bleeding disorder other than hemophilia A</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>Hemophilia A</keyword>
</DOC>